Are GLP-1 medications themselves peptides?

Yes. Both semaglutide and tirzepatide are peptide drugs. They are short chains of amino acids designed to act on receptors in your body that regulate appetite and blood sugar. The framing of "peptides plus GLP-1s" sounds like two separate categories, but biologically they are the same family used in different ways.

Did the FDA make wellness peptides legal in 2026?

No. The FDA removed 12 peptides from its Category 2 list in April 2026, but that move only changes one regulatory designation. Those peptides are still not FDA-approved and not yet approved for routine compounding. The agency is holding an advisory committee meeting in July 2026 to decide whether to add some of them to the separate list that compounding pharmacies are allowed to work with.

Can I add a wellness peptide to my GLP-1 medication safely?

There are no large human studies showing that combining wellness peptides with semaglutide or tirzepatide is safe or effective. If a clinic is recommending the combination, the right path is a registered clinician who can prescribe and a licensed compounding pharmacy that can make it. We do not recommend buying peptides from any source outside that system.

Are compounded GLP-1 products in the same category as wellness peptides?

No. Compounded GLP-1 products from a licensed 503A or 503B pharmacy operate under a specific legal framework that uses an FDA-approved comparator drug as the basis. The wellness peptides driving most of the current conversation are not yet approved for compounding and are mostly being sold outside that framework. The licensing of the pharmacy and the regulatory status of the ingredient are two different things.

What if my provider is recommending a peptide stack?

Ask for the exact name of each peptide, the source pharmacy, the dosage, and the clinical reasoning behind the combination. A registered clinician should be able to walk you through all four. If the answer relies on testimonials, social media, or company marketing rather than clinical evidence and a licensed pharmacy, that is your signal to slow down and get a second opinion.

Peptides and GLP-1s Together: What We Know Now

Updated: October 21, 2026

Nobody can promise it's safe to add a wellness peptide like BPC-157 to a GLP-1 drug. We could not find a single published human study that tested the two together. Even on its own, BPC-157 has so little human data that FDA staff said they could not describe its safety profile (FDA).

The rules have moved since we first wrote this in April. On October 14, an FDA plan for compounding certain peptides went to the Office of Management and Budget. That is the federal office that reviews proposed policies (OMB). As of October 20, none of the peptides the FDA reviewed this summer had been added to the official list of ingredients pharmacies may use (Holland & Knight).

Who This Helps

This guide is for you if you take Ozempic, Zepbound or a compounded GLP-1 product, or you plan to. Maybe you keep hearing about peptides that people use to build muscle, look younger or get more energy (STAT).

Nothing reported ties your GLP-1 prescription to the peptide plan

The plan under review has a narrow title, the "Interim Access Policy for Compounding Using Certain Peptides" (OMB). The public filing gives no details but there's no indication it will mention GLP-1s. But two people familiar with the plan told the Associated Press it would let pharmacies make popular peptides such as BPC-157 for a time (STAT). None of the reports we read through October 20 say it would change brand GLP-1 drugs or the rules for compounded GLP-1 products.

Ozempic and Zepbound are peptides too

Peptides are short chains of amino acids, the building blocks of protein (PolitiFact). Ozempic and Zepbound are peptides, and so is tesamorelin, another FDA-approved drug. Those approved peptides went through clinical trials. Most of the evidence for popular wellness peptides comes from animal studies. In wellness circles, a "stack" often means combining wellness peptides with each other, like BPC-157 with TB-500. In this post we use the word for adding a wellness peptide on top of a GLP-1 drug. That puts a much less studied product next to one that went through trials. Our guide to what peptides are and how they differ from GLP-1 drugs walks through the main types.

Find a provider in your state

Answer a few questions and see live pricing from the providers that ship where you live.

Get started

No human study has tested BPC-157 with a GLP-1

We looked for published human studies of BPC-157, TB-500 or other wellness peptides used with semaglutide or tirzepatide. As of October 20, 2026, we found none. Drugs in formal trials are a different case: cagrilintide, an amylin analog, has been tested with semaglutide in trials such as REDEFINE 1 (ADA Meeting News). That is a formal trial of two drugs, not a wellness stack.

Before a July advisory meeting, FDA staff went looking for human studies of BPC-157 (FDA). They found five, all small and short. None reported a serious side effect. Even so, the staff wrote that there was "insufficient clinical safety information to characterize the safety profile." They also flagged that injected or nasal BPC-157 could set off an immune reaction, though no study has tested that. They judged the risk from an oral dose likely low.

One small study reported that BPC-157 relieved knee pain in 14 of 16 patients. It had no comparison group, so the pain may simply have faded on its own (KFF Health News). The U.S. Anti-Doping Agency bans BPC-157 in sport. Because it has been studied so little in people, the agency says "it is unknown if there is a safe dose" (USADA).

What changed since April

In April, the FDA said it would take 12 peptides off its Category 2 list, the list of bulk ingredients that raise significant safety risks. The groups that first nominated them had withdrawn their requests (Holland & Knight). The change removed a safety label, but it "did not make any peptide eligible for compounding."

In July, an FDA advisory panel backed six of seven peptides for the list pharmacies use. BPC-157, KPV and TB-500 each passed 8 to 6, with one abstention (FDA Law Blog). FDA staff had said none of them had been studied enough to show they were safe and worked (STAT).

In August, the FDA sent warning letters to five online peptide sellers, several of which sold research-labeled versions of GLP-1 drugs (Holland & Knight; ArentFox Schiff). One letter said a "not intended for human or veterinary use" label did not change what the website showed. The products were meant for people (FDA).

On October 14, the interim peptide plan went to the same budget office for review (OMB). As of October 20 it was still listed as pending, so it is not in effect.

The interim policy would likely open a narrow door

The plan hasn't been published, and the public record does not show its text, which peptides it covers or its terms (Buchanan Ingersoll & Rooney). Holland & Knight expects it would most likely use "enforcement discretion," meaning the FDA chooses not to act against certain pharmacies. The firm notes that enforcement discretion "does not modify the underlying statutory framework or confer FDA approval on a compounded product" (Holland & Knight). The law would stay the same, the drugs would stay unapproved, and the FDA would step back.

The firm also expects the plan would not cover sellers of "research use only" vials, supplements or 503B facilities. It would not bind state boards of pharmacy and medicine, and it could be pulled back without a formal rule (Holland & Knight). Adding peptides to the FDA's official list would take a formal rule, which could take years (STAT). Hims & Hers and Noom have said they would offer peptides if federal access eases. We cover what to check at those checkouts in Peptides Are Coming to Telehealth Checkouts.

Today, none of the peptides the FDA panel reviewed in July, including BPC-157, has a federal path for pharmacies to compound it (Holland & Knight). Even if the plan is issued, a compounded BPC-157 would still be an unapproved drug with little human data. Your state's rules could still say no.

Compounded GLP-1s follow their own rules

Compounded drugs are not FDA-approved, and they're made under two federal pathways (FDA). State boards of pharmacy watch over 503A pharmacies day to day. The FDA oversees 503B outsourcing facilities, inspects them on a risk-based schedule, and holds them to federal manufacturing rules. Our 503A vs 503B guide explains how each one works. A "research use only" vial bought online sits outside both. Our report on black-market peptide vials that didn't match their labels shows what that can look like.

Five red flags in peptide marketing

KFF Health News checked common peptide claims against the evidence in an October 19 report (KFF Health News). Three of these flags come from that report, one from the FDA's August letters, and one from a law firm's advice to wellness companies.

"Peptides aren't drugs." Insulin is a peptide your body makes, and it's a drug when you inject it. A law professor told KFF that most drugs have natural roots.
"It's natural, so it's safe." Stanford peptide scientist Katrin Svensson told KFF that "natural things can be toxic." People have died from taking too much insulin.
"It heals injuries and treats illness." Few clinical trials back these claims. A lab result, like a peptide helping blood vessels grow, says nothing about safety in people, so statements like these should be given due scrutiny.
"Research use only" next to mixing supplies. The FDA pointed to one seller that sold bacteriostatic water, used to mix shots, beside a "peptide calculator." That showed the products were meant to be injected, the agency said (FDA).
"FDA-approved" or "fast-tracked." Holland & Knight tells wellness companies not to use those words for peptides still under review (Holland & Knight).

Bring the peptide's name to the clinician who prescribes your GLP-1

Ask what human studies exist for that exact peptide. Flynn McGuire, a University of Utah rehab doctor, has told his patients he won't prescribe BPC-157 until good studies exist (KFF Health News).
For your GLP-1, check that the pharmacy holds a state license. The FDA tells people who buy GLP-1 drugs online to use only state-licensed pharmacies (FDA). A license does not mean a pharmacy can lawfully compound BPC-157 today.
Look up the prescriber with your state medical board, through the Federation of State Medical Boards list (FSMB).
Skip any vial marked for lab or research use. Those labels did not stop the FDA from treating products as drugs for people, once the seller's website showed that is what they were for (FDA).

If you're comparing GLP-1 providers, our free provider quiz asks about your drug, the features you want and your state. Then it shows providers you can compare side by side.

What changed in this update

Updated October 2026 with the July panel votes, the August warning letters, the October plan filing and KFF Health News's check of peptide claims. We removed a line saying the FDA had flagged peptides sold to ease GLP-1 side effects; the FDA page we linked does not say that at the time of update. Next review: when the FDA issues or withdraws the interim peptide plan.

Final Takeaway

Ozempic and Zepbound are peptides, so adding a wellness peptide means stacking a well-studied drug with one that has far less behind it. We found no human study that tested BPC-157 or a similar peptide together with a GLP-1. The rules have moved since April. But none of the peptides the panel backed has been added to the compounding list, and the interim policy is still under review. Nothing reported so far suggests the plan would change your GLP-1 prescription, brand or compounded. Bring any peptide you're curious about to the clinician who knows your full medicine list.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

Frequently Asked Questions

Can I take BPC-157 with Ozempic or another GLP-1?

No one can say whether it's safe, because no human study we found has tested BPC-157 with a GLP-1 medication. BPC-157 itself has only a handful of small human studies, and FDA scientists said there's too little safety data to describe its risks. As of October 2026 it also hasn't been added to the FDA's list of ingredients that pharmacies may compound with.

Will the FDA's interim peptide policy affect my compounded GLP-1?

Nothing reported so far suggests it will. The policy under review covers "certain peptides," and the one named in news reports is BPC-157, a wellness peptide. Compounded GLP-1 products already follow their own rules for 503A pharmacies and 503B facilities.

Are any peptides FDA-approved?

Yes. Ozempic and Zepbound are peptides, and so is tesamorelin. Approved peptides went through clinical trials and FDA review. Most wellness peptides sold online have not. That said, some of the peptides that went through FDA review but are not yet cleared to sell from licensed pharmacies are showing up at some checkouts as the green light to prescribe becomes more likely.

Can You Take Peptides and GLP-1 Medications Together? What We Know Now (2026)